Merck, L5668-2ML, Lipopolysaccharides from Escherichia coli O127:B8

General description
This product is a 0.2 um filtered aqueous solution containing 1 mg/mL of lipopolysaccharides (LPS) from E. coli serotype O127:B8. This LPS serotype has been used in studies of septic shock, to induce neutrophils, to induce NOS in rat brain and induce PAF synthesis in rat glomerular mesangial cells.
Application
Lipopolysaccharides (LPSs) are characteristic components of the cell wall of Gram-negative bacteria. LPS and its lipid A moiety stimulate cells of the innate immune system by the Toll-like receptor 4 (TLR4), a member of the Toll-like receptor protein family, which recognizes common pathogen-associated molecular-patterns (PAMPs).
Biochem/physiol Actions
Lipopolysaccharides (LPS) are localized in the outer layer of the membrane and are, in noncapsulated strains, exposed on the cell surface. They contribute to the integrity of the outer membrane, and protect the cell against the action of bile salts and lipophilic antibiotics.
Preparation Note
The LPS used to prepare the solution have been phenol-extracted and chromatographically purified by gel filtration. Lipopolysaccharides prepared by phenol extraction contain up to 60% RNA and less than 1% protein. Subsequent purification by gel filtration chromatography removes much of protein present in the phenol-extracted LPS, but leaves a product that still contains 10-20% nucleic acids. Further purification using ion exchange chromatography yields an LPS product which contains <1% protein and <1% RNA.
Other Notes
To gain a comprehensive understanding of our extensive range of Lipopolysaccharides for your research, we encourage you to visit our Carbohydrates Category page.